Thus, across the DNET, MGNT and RGNT tumours, recurrent genomic alterations may exert their effect on OPC-like cells with elevated rat sarcoma/mitogen-activated protein kinase (RAS/MAPK) pathway activity. This evidence concerns the gene WNK2 and sarcoma.